​
​

LeMaitre Vascular (LMAT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LMAT Stock Forecast

LeMaitre Vascular stock forecast is as follows: an average price target of $85.25 (represents a -17.67% downside from LMAT’s last price of $103.55) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

LMAT Price Target

The average price target for LeMaitre Vascular (LMAT) is $85.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $70.00. This represents a potential -17.67% downside from LMAT's last price of $103.55.

LMAT Analyst Ratings

Buy

According to 2 Wall Street analysts, LeMaitre Vascular's rating consensus is 'Buy'. The analyst rating breakdown for LMAT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

LeMaitre Vascular Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 15, 2024Ross OsbornCantor Fitzgerald$96.00$92.144.19%-7.29%
Aug 20, 2024Daniel StauderJMP Securities$100.00$85.5316.92%-3.43%
Apr 26, 2024Rick WiseStifel Nicolaus$75.00$65.4614.57%-27.57%
Sep 06, 2023Suraj KaliaOppenheimer$70.00$56.7123.44%-32.40%
Row per page
Go to

The latest LeMaitre Vascular stock forecast, released on Oct 15, 2024 by Ross Osborn from Cantor Fitzgerald, set a price target of $96.00, which represents a 4.19% increase from the stock price at the time of the forecast ($92.14), and a -7.29% decrease from LMAT last price ($103.55).

LeMaitre Vascular Price Target by Period

1M3M12M
# Anlaysts-23
Avg Price Target-$98.00$90.33
Last Closing Price$103.55$103.55$103.55
Upside/Downside-100.00%-5.36%-12.77%

In the current month, the average price target of LeMaitre Vascular stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LeMaitre Vascular's last price of $103.55. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 01, 2024OppenheimerOutperformOutperformHold
Oct 15, 2024JMP SecuritiesNeutralNeutralHold
Oct 15, 2024Cantor FitzgeraldUnderperformUnderperformHold
Oct 15, 2024Cantor Fitzgerald-NeutralInitialise
Aug 20, 2024JMP SecuritiesOutperformOutperformHold
May 03, 2024JMP SecuritiesOutperformOutperformHold
Sep 06, 2023Oppenheimer-OutperformInitialise
Row per page
Go to

LeMaitre Vascular's last stock rating was published by Oppenheimer on Nov 01, 2024. The company gave LMAT a "Outperform" rating, the same as its previous rate.

LeMaitre Vascular Financial Forecast

LeMaitre Vascular Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$47.41M$50.12M$47.08M$40.95M$39.03M$42.11M$39.56M$39.50M$38.37M$40.67M$35.88M$37.55M$36.42M$24.85M$30.55M$30.17M$29.10M
Avg Forecast$66.60M$65.00M$66.50M$63.40M$62.06M$59.49M$60.99M$58.11M$55.98M$53.50M$54.98M$51.50M$49.01M$47.53M$48.08M$43.54M$41.00M$40.01M$41.39M$38.65M$39.64M$39.05M$39.57M$35.19M$35.58M$31.62M$17.12M$30.84M$30.43M$28.15M
High Forecast$67.62M$65.99M$67.52M$64.37M$63.01M$60.40M$61.93M$58.89M$56.54M$53.58M$54.98M$51.50M$49.67M$47.55M$48.82M$44.20M$41.62M$40.01M$41.39M$38.65M$39.64M$39.05M$39.57M$35.19M$35.58M$31.62M$17.12M$30.84M$30.43M$28.15M
Low Forecast$65.33M$63.76M$65.23M$62.19M$60.88M$58.36M$59.83M$57.20M$55.74M$53.43M$54.98M$51.50M$48.85M$47.50M$47.17M$42.71M$40.22M$40.01M$41.39M$38.65M$39.64M$39.05M$39.57M$35.19M$35.58M$31.62M$17.12M$30.84M$30.43M$28.15M
# Analysts33334446733475632222345611159988
Surprise %-------------1.00%1.04%1.08%1.00%0.98%1.02%1.02%1.00%0.98%1.03%1.02%1.06%1.15%1.45%0.99%0.99%1.03%

LeMaitre Vascular's average Quarter revenue forecast for Dec 23 based on 7 analysts is $49.01M, with a low forecast of $48.85M, and a high forecast of $49.67M. LMAT's average Quarter revenue forecast represents a 3.37% increase compared to the company's last Quarter revenue of $47.41M (Sep 23).

LeMaitre Vascular EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33334446733475632222345611159988
EBITDA-------------$9.37M$9.63M$8.91M$7.80M$6.41M$9.06M$8.04M$11.31M$11.98M$13.59M$10.69M$12.04M$12.73M$6.47M$5.82M$6.63M$7.24M
Avg Forecast$17.26M$16.84M$17.23M$16.43M$16.08M$15.42M$15.81M$15.06M$14.51M$13.86M$14.25M$13.13M$12.70M$12.32M$12.46M$11.94M$13.65M$8.53M$8.82M$10.85M$8.45M$8.32M$8.44M$10.30M$7.59M$6.74M$3.65M$5.43M$6.49M$6.00M
High Forecast$17.52M$17.10M$17.50M$16.68M$16.33M$15.65M$16.05M$15.26M$14.65M$13.88M$14.25M$15.76M$12.87M$12.32M$12.65M$14.32M$16.38M$8.53M$8.82M$13.02M$8.45M$8.32M$8.44M$12.36M$7.59M$6.74M$3.65M$6.52M$6.49M$6.00M
Low Forecast$16.93M$16.52M$16.90M$16.12M$15.77M$15.12M$15.50M$14.82M$14.44M$13.84M$14.25M$10.50M$12.66M$12.31M$12.22M$9.55M$10.92M$8.53M$8.82M$8.68M$8.45M$8.32M$8.44M$8.24M$7.59M$6.74M$3.65M$4.34M$6.49M$6.00M
Surprise %-------------0.76%0.77%0.75%0.57%0.75%1.03%0.74%1.34%1.44%1.61%1.04%1.59%1.89%1.77%1.07%1.02%1.21%

7 analysts predict LMAT's average Quarter EBITDA for Dec 23 to be $12.70M, with a high of $12.87M and a low of $12.66M. This is 35.55% upper than LeMaitre Vascular's previous annual EBITDA (Sep 23) of $9.37M.

LeMaitre Vascular Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33334446733475632222345611159988
Net Income-------------$7.50M$8.10M$6.04M$5.63M$5.46M$3.52M$6.04M$6.17M$6.50M$8.30M$5.93M$7.03M$7.51M$3.50M$3.17M$4.61M$5.18M
Avg Forecast$13.93M$12.90M$13.47M$12.79M$12.99M$12.07M$12.90M$11.53M$11.24M$9.93M$10.77M$7.57M$8.12M$7.05M$7.23M$6.88M$7.45M$6.17M$5.77M$6.25M$6.96M$7.39M$7.99M$5.71M$6.67M$4.41M$151.51K$2.96M$5.16M$4.74M
High Forecast$14.21M$13.16M$13.74M$13.04M$13.25M$12.31M$13.16M$12.21M$11.69M$9.96M$10.77M$9.08M$8.28M$7.13M$7.37M$8.25M$8.94M$6.17M$5.77M$7.50M$6.96M$7.39M$7.99M$6.85M$6.67M$4.41M$151.51K$3.55M$5.16M$4.74M
Low Forecast$13.59M$12.58M$13.14M$12.47M$12.67M$11.78M$12.58M$11.08M$10.96M$9.91M$10.77M$6.05M$7.89M$6.97M$7.05M$5.50M$5.96M$6.17M$5.77M$5.00M$6.96M$7.39M$7.99M$4.57M$6.67M$4.41M$151.51K$2.37M$5.16M$4.74M
Surprise %-------------1.06%1.12%0.88%0.76%0.88%0.61%0.97%0.89%0.88%1.04%1.04%1.06%1.70%23.10%1.07%0.89%1.09%

LeMaitre Vascular's average Quarter net income forecast for Dec 23 is $8.12M, with a range of $7.89M to $8.28M. LMAT's average Quarter net income forecast represents a 8.24% increase compared to the company's last Quarter net income of $7.50M (Sep 23).

LeMaitre Vascular SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33334446733475632222345611159988
SG&A-------------$17.41M$17.94M$18.83M$15.53M$15.46M$15.57M$15.10M$14.20M$12.95M$13.00M$13.01M$11.99M$11.06M$10.02M$13.14M$12.48M$11.98M
Avg Forecast$25.05M$24.45M$25.02M$23.85M$23.34M$22.38M$22.94M$21.86M$21.06M$20.13M$20.68M$18.93M$18.44M$17.88M$18.09M$17.21M$17.13M$14.80M$15.31M$15.64M$14.67M$14.45M$14.64M$12.53M$13.16M$11.70M$6.34M$12.26M$11.26M$10.42M
High Forecast$25.44M$24.83M$25.40M$24.21M$23.70M$22.72M$23.30M$22.15M$21.27M$20.16M$20.68M$22.71M$18.68M$17.89M$18.36M$20.65M$20.56M$14.80M$15.31M$18.77M$14.67M$14.45M$14.64M$15.03M$13.16M$11.70M$6.34M$14.71M$11.26M$10.42M
Low Forecast$24.58M$23.99M$24.54M$23.40M$22.90M$21.95M$22.51M$21.52M$20.97M$20.10M$20.68M$15.14M$18.38M$17.87M$17.74M$13.76M$13.70M$14.80M$15.31M$12.51M$14.67M$14.45M$14.64M$10.02M$13.16M$11.70M$6.34M$9.81M$11.26M$10.42M
Surprise %-------------0.97%0.99%1.09%0.91%1.04%1.02%0.97%0.97%0.90%0.89%1.04%0.91%0.95%1.58%1.07%1.11%1.15%

LeMaitre Vascular's average Quarter SG&A projection for Dec 23 is $18.44M, based on 7 Wall Street analysts, with a range of $18.38M to $18.68M. The forecast indicates a 5.88% rise compared to LMAT last annual SG&A of $17.41M (Sep 23).

LeMaitre Vascular EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33334446733475632222345611159988
EPS-------------$0.34$0.36$0.27$0.26$0.25$0.16$0.28$0.28$0.30$0.40$0.29$0.35$0.37$0.17$0.16$0.23$0.26
Avg Forecast$0.61$0.56$0.59$0.56$0.57$0.53$0.56$0.51$0.49$0.43$0.47$0.39$0.36$0.31$0.32$0.25$0.26$0.27$0.25$0.28$0.31$0.33$0.35$0.27$0.29$0.19$0.01$0.16$0.23$0.21
High Forecast$0.62$0.58$0.60$0.57$0.58$0.54$0.58$0.53$0.51$0.44$0.47$0.39$0.36$0.31$0.32$0.25$0.26$0.27$0.25$0.28$0.31$0.33$0.35$0.27$0.29$0.19$0.01$0.16$0.23$0.21
Low Forecast$0.59$0.55$0.58$0.55$0.55$0.52$0.55$0.49$0.48$0.43$0.47$0.39$0.35$0.31$0.31$0.24$0.25$0.27$0.25$0.28$0.31$0.33$0.35$0.27$0.29$0.19$0.01$0.16$0.23$0.21
Surprise %-------------1.10%1.14%1.08%1.02%0.92%0.63%1.01%0.91%0.92%1.14%1.07%1.19%1.91%25.50%1.01%1.01%1.25%

According to 7 Wall Street analysts, LeMaitre Vascular's projected average Quarter EPS for Dec 23 is $0.36, with a low estimate of $0.35 and a high estimate of $0.36. This represents a 4.59% increase compared to LMAT previous annual EPS of $0.34 (Sep 23).

LeMaitre Vascular Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
COOCooper Companies$99.48$298.00199.56%Buy
HAEHaemonetics$88.17$108.2522.77%Buy
NVSTEnvista$20.61$23.1112.13%Hold
KRMDKORU Medical Systems$3.15$3.253.17%Buy
HOLXHologic$78.79$80.211.80%Buy
ICUIICU Medical$169.98$172.001.19%Buy
LMATLeMaitre Vascular$103.55$85.25-17.67%Buy

LMAT Forecast FAQ

Is LeMaitre Vascular a good buy?

Yes, according to 2 Wall Street analysts, LeMaitre Vascular (LMAT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of LMAT's total ratings.

What is LMAT's price target?

LeMaitre Vascular (LMAT) average price target is $85.25 with a range of $70 to $100, implying a -17.67% from its last price of $103.55. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will LeMaitre Vascular stock go up soon?

According to Wall Street analysts' prediction for LMAT stock, the company can go down by -17.67% (from the last price of $103.55 to the average price target of $85.25), down by -3.43% based on the highest stock price target, and down by -32.40% based on the lowest stock price target.

Can LeMaitre Vascular stock reach $200?

LMAT's average twelve months analyst stock price target of $85.25 does not support the claim that LeMaitre Vascular can reach $200 in the near future.

What are LeMaitre Vascular's analysts' financial forecasts?

LeMaitre Vascular's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $240.66M (high $244.22M, low $236.27M), average EBITDA is $62.36M (high $63.29M, low $61.23M), average net income is $49.5M (high $50.93M, low $48.11M), average SG&A $90.53M (high $91.87M, low $88.88M), and average EPS is $2.17 (high $2.23, low $2.11). LMAT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $261.5M (high $265.5M, low $256.52M), average EBITDA is $67.76M (high $68.8M, low $66.47M), average net income is $53.09M (high $54.15M, low $51.78M), average SG&A $98.37M (high $99.87M, low $96.5M), and average EPS is $2.32 (high $2.37, low $2.27).

Did the LMAT's actual financial results beat the analysts' financial forecasts?

Based on LeMaitre Vascular's last annual report (Dec 2023), the company's revenue was $193.48M, beating the average analysts forecast of $188.16M by 2.83%. Apple's EBITDA was $36.71M, missing the average prediction of $49.41M by -25.70%. The company's net income was $30.1M, beating the average estimation of $29.28M by 2.83%. Apple's SG&A was $72.89M, beating the average forecast of $71.61M by 1.78%. Lastly, the company's EPS was $1.34, beating the average prediction of $1.23 by 8.87%. In terms of the last quarterly report (Sep 2023), LeMaitre Vascular's revenue was $47.41M, missing the average analysts' forecast of $47.53M by -0.25%. The company's EBITDA was $9.37M, missing the average prediction of $12.32M by -23.93%. LeMaitre Vascular's net income was $7.5M, beating the average estimation of $7.05M by 6.40%. The company's SG&A was $17.41M, missing the average forecast of $17.88M by -2.62%. Lastly, the company's EPS was $0.34, beating the average prediction of $0.309 by 10.12%